A single-cycle, recombinant VSV platform Nipah vaccine cross-protects against Hendra virus in nonhuman primates
PLOS Pathogens · 2026
DOI: 10.1371/journal.ppat.1014646 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2026. Verfasst von Declan D Pigeaud und 11 weiteren Autor:innen. Beteiligte Einrichtung: Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, United States of America. Hauptthemen laut MEDLINE: Nipah Virus, Henipavirus Infections, Hendra Virus, Viral Vaccines. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, University of Texas Medical Branch at Galveston, National Institutes of Health.
Abstract (Originalsprache)
Nipah virus (NiV) and Hendra virus (HeV) are highly pathogenic paramyxoviruses that produce severe, often fatal disease in humans and animals. Zoonotic spillover of these henipaviruses from the Pteropid bat natural reservoir occurs near-annually in Southeast Asia and Oceania. Outbreaks of NiV disease frequently exceed case fatality rates of 75%, and person-to-person transmission makes controlling outbreaks in low-resource environments challenging. HeV is less transmissible between humans; however, the overall mortality rate is 57%. Approaches to human vaccine development have largely focused on NiV given the larger case burden, and immunogen selection has centered on display of the NiV attachment (G) or fusion (F) surface glycoproteins. However, experimental vaccines displaying these NiV antigens have failed to uniformly cross-protect against HeV disease in preclinical models. The HeV (G) antigen was shown to cross-protect against both HeV and NiV when delivered in a protein subunit form; however, attempts to utilize mRNA or canarypox vectors failed to achieve equivalent protection. We previously developed and evaluated a single-cycle recombinant vesicular stomatitis virus-vectored vaccine displaying the (G) glycoprotein of Nipah virus strain Bangladesh (NiV-B). This experimental vaccine (G*rVSV∆G-NiV-G) demonstrated ideal characteristics of rapid and durable protection against NiV-B challenge in nonhuman primates. In the present work, we show that the G*rVSV∆G-NiV-G vaccine cross-protects against lethal HeV challenge, with the protective response driven by a balance of both cell-mediated and humoral compartments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, United States of America.
- Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.
ORCID-Profile: Thomas W Geisbert
Förderung
- NIAID NIH HHS
- University of Texas Medical Branch at Galveston
- National Institutes of Health
Zitieren
APA
Pigeaud, D. D., Borisevich, V., Turcinovic, J., Agans, K. N., Deer, D. J., Harrison, M. B., O'Toole, R., Dobias, N. S., Prasad, A. N., Fenton, K. A., Cross, R. W., & Geisbert, T. W. (2026). A single-cycle, recombinant VSV platform Nipah vaccine cross-protects against Hendra virus in nonhuman primates. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1014646
Vancouver
Pigeaud DD, Borisevich V, Turcinovic J, Agans KN, Deer DJ, Harrison MB, et al. A single-cycle, recombinant VSV platform Nipah vaccine cross-protects against Hendra virus in nonhuman primates. PLOS Pathogens. 2026. doi:10.1371/journal.ppat.1014646
BibTeX
@article{Pigeaud2026,
author = {Pigeaud, Declan D and Borisevich, Viktoriya and Turcinovic, Jacquelyn and Agans, Krystle N and Deer, Daniel J and Harrison, Mack B and O'Toole, Rachel and Dobias, Natalie S and Prasad, Abhishek N and Fenton, Karla A and Cross, Robert W and Geisbert, Thomas W},
title = {A single-cycle, recombinant VSV platform Nipah vaccine cross-protects against Hendra virus in nonhuman primates},
journal = {PLOS Pathogens},
year = {2026},
doi = {10.1371/journal.ppat.1014646}
}
EUVIMED